361 related articles for article (PubMed ID: 26050703)
1. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant Acinetobacter baummannii in critically ill cancer patients: a retrospective cohort study.
Nazer LH; Rihani S; Hawari FI; Le J
Infect Dis (Lond); 2015; 47(11):755-60. PubMed ID: 26050703
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
4. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
7. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.
Bassetti M; Repetto E; Righi E; Boni S; Diverio M; Molinari MP; Mussap M; Artioli S; Ansaldi F; Durando P; Orengo G; Bobbio Pallavicini F; Viscoli C
J Antimicrob Chemother; 2008 Feb; 61(2):417-20. PubMed ID: 18174197
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
[TBL] [Abstract][Full Text] [Related]
9. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
10. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan.
Lin CC; Liu TC; Kuo CF; Liu CP; Lee CM
J Microbiol Immunol Infect; 2010 Aug; 43(4):323-31. PubMed ID: 20688293
[TBL] [Abstract][Full Text] [Related]
11. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
Amat T; Gutiérrez-Pizarraya A; Machuca I; Gracia-Ahufinger I; Pérez-Nadales E; Torre-Giménez Á; Garnacho-Montero J; Cisneros JM; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24(6):630-634. PubMed ID: 28970161
[TBL] [Abstract][Full Text] [Related]
12. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study.
Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T
J Infect Public Health; 2023 Aug; 16(8):1249-1255. PubMed ID: 37295057
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients.
Trottier V; Namias N; Pust DG; Nuwayhid Z; Manning R; Marttos AC; Dunham MB; Schulman CI; McKenney MG
Surg Infect (Larchmt); 2007 Aug; 8(4):437-43. PubMed ID: 17883360
[TBL] [Abstract][Full Text] [Related]
14. Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.
Turkoglu M; Dizbay M; Ciftçi A; Aksakal FN; Aygencel G
Int J Antimicrob Agents; 2012 Feb; 39(2):142-5. PubMed ID: 22115538
[TBL] [Abstract][Full Text] [Related]
15. [Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients].
Pérez-Pedrero MJ; Sánchez-Casado M; Rodríguez-Villar S
Med Intensiva; 2011 May; 35(4):226-31. PubMed ID: 21396739
[TBL] [Abstract][Full Text] [Related]
16. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
Durante-Mangoni E; Signoriello G; Andini R; Mattei A; De Cristoforo M; Murino P; Bassetti M; Malacarne P; Petrosillo N; Galdieri N; Mocavero P; Corcione A; Viscoli C; Zarrilli R; Gallo C; Utili R
Clin Infect Dis; 2013 Aug; 57(3):349-58. PubMed ID: 23616495
[TBL] [Abstract][Full Text] [Related]
17. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
[TBL] [Abstract][Full Text] [Related]
18. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
Yilmaz GR; Guven T; Guner R; Kocak Tufan Z; Izdes S; Tasyaran MA; Acikgoz ZC
J Infect Dev Ctries; 2015 May; 9(5):476-85. PubMed ID: 25989167
[TBL] [Abstract][Full Text] [Related]
19. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
20. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.
Petrosillo N; Chinello P; Proietti MF; Cecchini L; Masala M; Franchi C; Venditti M; Esposito S; Nicastri E
Clin Microbiol Infect; 2005 Aug; 11(8):682-3. PubMed ID: 16008625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
